Andrew D Zelenetz, MD, PhD

Medical Director, Quality Informatics

Attending Physician, Lymphoma Service

Department of Medicine

Memorial Sloan Kettering Cancer Center

1275 York Avenue

New York, NY  10065

Andrew D. Zelenetz, MD, PhD, is the Medical Director of Quality Informatics at Memorial Sloan Kettering Cancer Center in New York.  Prior to that, he had held the positions of Vice Chair, Medical informatics from January 2013 to May 2016 and Chief, Lymphoma Service in the Division of Hematology/Oncology at MSKCC from 1994-December 2012.  He is also a Professor of Medicine at Weill Cornell Medical College.

He has helped develop a number of the agents now approved to treat lymphoma — including 131I-tosituomab/tositumomab, bortezomib, and pralatrexate — and through clinical studies he is evaluating the benefits of novel combinations of agents. In another area of research, he is working to improve the prognostic value of patients’ pathology specimens using computer-aided image analysis. He has published more than 100 papers on lymphoma research in journals such as Blood, Journal of Clinical Oncology and Clinical Cancer Research.

Dr. Zelenetz received his BA from Harvard College, his PhD from Harvard University’s Graduate School of Arts and Sciences, Division of Medical Sciences and his MD from Harvard Medical School.  Both his internship and residency in medicine were completed at Stanford University Medical Center as well as a clinical fellowship and research fellowship in oncology.

Dr. Zelenetz is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American College of Physicians. He participates in various committees: he was Vice Chairperson of the Cancer and Leukemia Group B Lymphoma Core Committee and Chair of the Lymphoma Research Foundation Scientific Advisory Board.  He is also the Chair of the NCCN Non-Hodgkin’s Lymphoma Panel and Board Member of the Leukemia and Lymphoma Society.  He has been the recipient of the Memorial Sloan Kettering Fellowship Teaching Excellence Award multiple times and has received the Rodger Winn Award from the National Comprehensive Cancer Network in 2012.